PC-Pool, and PCUnion approachespound Irinotecan Topotecan Panobinostat AZD6244 PD-Target(s) TOP1 TOP1 HDAC MEK MEKNo. of PC-Meta Markers 211 757 542 10No. of PC-Pool Markers (Overlap with PC-Meta) 832 (105; 13 ) 474 (256; 54 ) 723 (200; 28 ) 51 (6; 12 ) 46 (23; 50 )No. of PC-Union Markers (Overlap with PC-Meta) 30 (19; 63 ) 61 (57; 93 ) 58 (46; 79 ) 7 (1; 14 ) 156 (29; 19 )doi:10.1371/journal.pone.0103050.tPLOS One | plosone.orgCharacterizing Pan-Cancer Mechanisms of Drug SensitivityFigure 3. Best markers of response to TOP1 inhibitors: (A) SLFN11 and (B) HMGB2. Scatter plots show correlation in between gene expression and pharmacological response values across a number of cancer lineages, exactly where up-regulation of SLFN11 and HMGB2 correlate with drug sensitivity (indicated by smaller sized IC50 values). doi:10.1371/journal.pone.0103050.gPLOS One particular | plosone.orgCharacterizing Pan-Cancer Mechanisms of Drug SensitivityPLOS 1 | plosone.orgCharacterizing Pan-Cancer Mechanisms of Drug SensitivityFigure 4. Pan-cancer evaluation of TOP1 inhibitor Topotecan. (A) Pan-cancer pathways with considerable involvement in drug response detected by PC-Meta, PC-Pool, PC-Union approaches (on the left). These pathways might be grouped into six biological processes (distinguished by background colour), which converge on two distinct mechanisms. The involvement amount of these pan-cancer pathways predicted by distinct approaches is illustrated with blue horizontal bars. Pathway involvement in every single cancer lineage predicted by PC-Meta is indicated by the intensity of red fills in corresponding table (on the ideal). Pan-cancer and lineage-specific pathway involvement (PI) scores are derived from pathway enrichment analysis and calculated as -log10(BH-adjusted p-values). Only the prime pathways with PI scores .1.three are shown. Cancer lineage abbreviations ?AU: autonomic; BO: bone; BR: breast; CN: central nervous program; EN: endometrial; HE: haematopoetic/lymphoid; KI: kidney; LA: substantial intestine; LI: liver; LU: lung; OE: oesophagus; OV: ovary; PA: pancreas; PL: pleura; SK: skin; SO: soft tissue; ST: stomach; TH: thyroid; UP: upper digestive; UR: urinary (B) Predicted known and novel mechanisms of intrinsic response to TOP1 inhibition. Red- and green-fill indicate enhanced and decreased activity in drug-resistant cell-lines respectively.Buy191347-94-1 (C) Heatmap displaying the expression of genes inside the cell cycle, nucleotide synthesis, and DNA damage repair pathways correlated with Topotecan response in numerous cancer lineages.1363210-41-6 site doi:ten.PMID:23329319 1371/journal.pone.0103050.gtheir roles in each and every cancer lineage. A subset of pan-cancer markers drastically correlated with response in every cancer variety had been chosen as `lineage-specific markers’. Then, every single set of lineagespecific markers was assessed for enrichment to calculate a PI score for each and every pan-cancer pathway in every single lineage. Interestingly, the pan-cancer pathways relevant to Topotecan response exhibited clear lineage-specific variations (Figure 4A). Intrinsic responsein urinary, ovarian and huge intestine cancers appeared prominently influenced via many mechanisms including cell cycle regulation, nucleotide synthesis, and DNA repair pathways (Figure 4C), whereas response in central nervous method cancers mostly involved EIF2 signaling. One-third on the cancer lineages were not characterized by any pan-cancer response mechanisms. Lineages devoid of considerable PI scores typically hadTable two. Component genes of top pan-cancer pathways connected with.